Navigation Links
Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Date:7/1/2008

REHOVOT, Israel, July 1 /PRNewswire-FirstCall/ -- Applisonix LTD (TASE: APLS), a developer of innovative ultrasound based solutions for the aesthetic market, announced today that the test conducted using its hair removal prototype achieved, following an initial treatment, average hair reduction of 38%, which positions its efficacy within the top professional long-term hair removal solutions.

Applisonix' co-CEOs, Mr. Alon Goren and Mr. Uri Amir, stated that the test results indicate that the technology developed by Applisonix can be safely and effectively implemented for men and women. Mr. Goren estimates that compared to commercially available long-term hair removal solutions, Applisonix' solutions are planned to be safer, less painful, more affordable, and applicable to all hair and skin tones, Mr. Amir added that the company intends to launch its first device, Selectif(TM), in the first quarter of 2009, as planned.

Applisonix conducted tests on men and women for a period of several months. The test results were examined by Prof. Kassuto (Milan, Italy), an external, independent, internationally recognized expert. Prof. Kassuto verified and evaluated the findings and concluded that the new technology's efficacy is similar to the efficacy of the top commercial light based systems, and without any side effects, and regardless of hair and skin color.

In addition, it appears from Prof. Kassuto's review, that following the initial treatment using the prototype and Applisonix' technology (IMPRESA(TM)), there was an average 38% hair reduction, compared to the controlled area, which was not treated. The treatment was given to 36 people, men and women, with different hair colors and skin tones, and the results were statistically significant.

These results reflect the new technology's capability of competing with expensive professional light-based systems. From studies published in this field, it seems that with most light based systems, one
'/>"/>

SOURCE Applisonix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Silence Therapeutics Announces Board Changes
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
7. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire/-- ChemoCentryx,Inc.,announcedtodaythatPha...rospectiveRandomizedOralTherapyEvaluationinCrohn,s...withmoderate-to-severeCrohn,sdiseasedemonstratedcl...rofile.Thestudydemonstratedevidenceofclinicaleffic...ointdecreaseintheCrohn,sDiseaseActivityIndex(CDAI)...
(Date:11/24/2009)...-FirstCall/--Endologix,Inc.(Nasdaq: ELGX ),develop...announcedtodaythatithasfiledamotiontostay,ordiscon...broughtagainstitinOctober2009byCook,Inc.Themotionw...s,Indiana. ,, Endologixhasrequestedthatthestayr...kOffice(USPTO)conductsproceedingstore-examinethetw...
(Date:11/24/2009)...tCall/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )a...JaffrayHealthcareConferenceonTuesday,December1,200...ldatTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Presi...overviewofAnadysanditsclinicaldevelopmentprograms,...lbesimultaneouslywebcastandcanbeaccessedontheInves...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 1Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 1Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 6Government of Canada supports research to help address medical isotope shortage 49067 1
(Date:11/26/2009)...of the Live Life Again Center, a practice offering...ing number of physicians who are taking advantage...h individuals who are interested in surgical weigh...is utilizing Facebook to share before-and-after ph...ommunity. , Dallas, TX (V...
(Date:11/25/2009).../--TheBartleHallConventionCenterwilltemporarilybec...ansasCityhoststhelatestinaseriesofmassivefreeclini...sthepotentialtobethebiggestoneyet,becauseitwillext...nsteadofoveraweekend,"SheriWood,executivedirectoro...ionalAssociationofFreeClinics(NAFC). ,, Atprevi...
(Date:11/25/2009)...re-USNewswire/--AnarticlebyJanetWoodcock,M.D.,dire...itled"ADifficultBalance-PainManagement,DrugSafety,...landJournalofMedicine. ,, (Logo: http://www.new...hearticle,WoodcockdiscussesFDAeffortstostrikeabala...ndmanagingtherisksposedbyvariousanalgesics.Asexamp...
(Date:11/25/2009)...tatistically significant survival benefit from adj...ptor (ER)-positive tumors had high levels of phosp...18-P), according to a brief communication publishe...al Cancer Institute . , Approximately 50% of bre...ical studies have shown that ER-alpha S118-P is re...
(Date:11/25/2009)... treatment clinics to resume Monday, Nov. 30 , ...5, 2009 -- Centegra Health System is continuing to...at four Centegra Primary Care (CPC) vaccination cl...d. The clinics are at CPC sites in Huntley, Woodst...follows: ,   From 4:30 to 7:30 p.m. Tu...
Breaking Medicine News(10 mins):Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...echniques of soft condensed matter physics, a rese...finely tuned balance of attractions between protei... even a small change in this balance can cause pro...gregation diseases (such as Alzheimers disease), a...
...007) New research published in the November issue...s shows that urban colorectal and lung cancer pati... patients do. This finding is contrary to the com...nts presenting with metastatic cancer is alarming,...
... 9 Hooper Holmes,Inc. (Amex: HH ), a leading pro...unced financial results for the third quarter ende...were $56.3 million compared to $60.6,million in th... loss of $42.1 million or $(0.63) per share in the...
... Pharmaceutical product teams,have the power to m...lem is,launch teams often lack the right structure...fore only produce a sub-optimal launch. In fact, ...ialization. According to a study by pharmaceutical...
...y Distributing over 12 Million Narcotic Pain,Pills...ney Matt M. Dummermuth announced today that six me...istribute controlled substances through an,Interne... Rapids. The indictment also seeks forfeiture of m...
...now be mapped less to mathematical standards and m...y by researchers at Harvard and Johns Hopkins Univ...onal Biology on November 9, 2007, provides a new p...cancer has long been based on streamlined models w...
Other Medicine News:Health News:Physics provides new insights on cataract formation 2Health News:Study reveals differences in cancer stage presentation between rural and urban patients 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2
...ears -- and works! Baby Gender Mentor Home DNA Gen...nology to attain the earliest gender detection wit...cy. The technique traces the amount of Y chromosom...Here's how it works: Your baby releases its DNA in...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
...mbrane glycoprotein associated with tyrosine kinas...ancer show an amplification and/or over-expression...on of Herceptin® as a targeted therapy for bre...reast carcinoma has become very important in patie...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
Medicine Products: